Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor

Last September, Bristol Myers Squibb brought a new type of autoimmune drug to market with big expectations. Called Sotyktu, it’s the first TYK2 inhibitor, medicines that are oral alternatives to top-selling injectable medicines. Discover more…